secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0000950170-22-016857
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio doses first SCD patient with nula-cel; Q2 net loss $25.9M, cash $328.3M
--------------------------------------------------------------------------------

- Dosed first patient in Phase 1/2 CEDAR trial of nula-cel for sickle cell disease; initial proof-of-concept data expected mid-2023.
- Cash, cash equivalents and marketable securities of $328.3M as of June 30, 2022; cash runway into Q4 2024.
- Q2 2022 net loss of $25.9M ($0.48 per share); R&D expenses $17.8M, G&A $9.0M.
- Nula-cel received FDA Fast Track designation for SCD; also has Orphan Drug designation.
- Preclinical data for GPH102 in beta-thalassemia presented at ASGCT; IND planned by mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000095017022016857/0000950170-22-016857-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000095017022016857/grph-20220811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016857

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer